BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting
Provided By PR Newswire
Last update: Oct 28, 2024
Biomarker data suggest ALS patients may benefit from longer-term treatment with NurOwn
Poster highlighting design of planned Phase 3b NurOwn trial also presented
Read more at prnewswire.comNASDAQ:BCLI (4/22/2025, 11:37:47 AM)
0.8615
+0 (+0.17%)
Find more stocks in the Stock Screener
BCLI Latest News and Analysis
11 days ago - ChartmillOn Friday, there are stocks with unusual volume. Let's take a look.Unusual volume stocks in Friday's session
